Amarin Corporation plc - American Depositary Shares (AMRN)
AMRN moved a median of +0.30% 30 minutes after news, and +0.14% by the close. How AMRN actually reacts to news — the realized, point-in-time move the market made, measured across 211 labeled events over the last three years with zero look-ahead.
AMRN’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | +0.06% | 51% | 208 |
| 30-min | +0.30% | 55% | 211 |
| 60-min | +0.15% | 53% | 211 |
| to close | +0.14% | 53% | 211 |
| Middle 50% of AMRN reactions | -1.64% to +1.78% |
|---|---|
| Median reaction (30-min) | +0.30% |
| Measured reactions | 211 |
Half of all Amarin Corporation plc - American Depositary Shares news events land between -1.64% and +1.78% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How AMRN reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst upgrades | 11 | +0.70% | 55% | -1.34% |
| Analyst downgrades | 13 | -0.03% | 39% | -0.19% |
| Coverage initiations | 11 | 0.00% | 36% | -0.48% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 3 further classes were observed with fewer than 10 measured events and are not published. See how AMRN ranks against every other measured name →
That’s how AMRN usually reacts — get an email when it moves on news →Email me when AMRN moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to AMRN's baseline. Nothing else.
Recent AMRN events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Amarin Highlights New REDUCE-IT® and Mechanistic Data Presented at European Society of Cardiology (ESC) Congress 2026 | Press release | GlobeNewswire | +2.50% | -0.64% | |
| New REDUCE-IT® Legacy Analysis Presented at European Society of Cardiology (ESC) Congress 2026 Suggests Persistent Cardiovascular Benefit Following Icosapent Ethyl Treatment Cessation in Adherent Patients | Press release | GlobeNewswire | -0.99% | -1.27% | |
| New Analyses from REDUCE-IT® and EPA Mechanistic Data to be Presented at the European Society of Cardiology (ESC) Congress 2026 | Press release | GlobeNewswire | -0.53% | -1.77% | |
| Amarin Reports 2026 Second Quarter Financial Results Demonstrating Early Success of Fully Partnered International Commercial Strategy and Continued Leading U.S. Market Presence | Press release | GlobeNewswire | -1.57% | +1.29% | |
| Amarin to Report Second Quarter 2026 Financial Results and Host Conference Call on July 29, 2026 | Press release | GlobeNewswire | +0.07% | +0.77% | |
| Amarin Reaffirms the Proven, Guideline-Recommended Role of VASCEPA® (Icosapent Ethyl) in an Evolving Triglyceride Treatment Landscape | Press release | GlobeNewswire | -0.44% | +3.65% | |
| New REDUCE-IT® Analysis Presented at the European Atherosclerosis Society (EAS) Congress 2026 Suggests Risk-Weighted ApoB May Improve Identification of Residual Cardiovascular Risk in Statin-Treated Patients with Hypertriglyceridemia | Press release | GlobeNewswire | +0.00% | +0.14% | |
| Amarin Reports 2026 First Quarter Financial Results | Press release | GlobeNewswire | +1.51% | +2.81% | |
| Amarin to Report First Quarter 2026 Financial Results and Host Conference Call on April 29, 2026 | Press release | GlobeNewswire | +0.00% | +4.97% | |
| American College of Cardiology (ACC) Scientific Sessions 2026 Underscore the Need for Complementary Therapies Including Icosapent Ethyl (IPE) in Treatment of Elevated Triglycerides and Cardiovascular Risk Reduction | Press release | GlobeNewswire | +0.00% | -1.34% | |
| Amarin Highlights Guideline Recommended Role of Icosapent Ethyl in Managing Cardiovascular Risk Following Release of Updated 2026 ACC/AHA/Multisociety Dyslipidemia Guideline | Press release | GlobeNewswire | +0.00% | -3.11% | |
| New REDUCE-IT Data in Patients at Extreme Cardiovascular Risk and In Vitro Research on the Mechanistic Effects of Eicosapentaenoic Acid (EPA) on Lipoprotein(a) [Lp(a)] Oxidation to be Presented at the American College of Cardiology’s (ACC) Annual Scientif | Press release | GlobeNewswire | +1.75% | -0.26% | |
| Effects of Icosapent Ethyl on Risk and Duration of Hospitalizations and Death in REDUCE-IT® Post Hoc Analysis Published in the European Journal of Preventive Cardiology | Press release | GlobeNewswire | +2.07% | +3.11% | |
| Form 10-K AMARIN CORP PLC\UK For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -0.15% | +4.59% | |
| Amarin Reports Fourth Quarter and Full Year 2025 Financial Results | Press release | GlobeNewswire | -2.93% | -8.53% | |
| Form 8-K AMARIN CORP PLC\UK For: Feb 25 | SEC filing · Form 8-K | SEC EDGAR | -2.93% | -8.53% | |
| This American Heart Month Amarin Spotlights the Need to Prioritize Proven Widely Available Yet Underutilized Therapies in the Battle Against Cardiovascular Disease | Press release | GlobeNewswire | +0.00% | +0.97% | |
| Amarin to Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on February 25, 2026 | Press release | GlobeNewswire | +1.74% | +1.34% | |
| Amarin Applauds Breakthroughs In Therapies For Patients With Elevated Triglycerides; Company’s VASCEPA®/VAZKEPA® (Icosapent Ethyl) Franchise Well Positioned To Benefit Globally From Broadened Category Commercialization | Press release | GlobeNewswire | -1.82% | -4.18% | |
| Amarin Announces Preliminary 2025 Financial Highlights and Operational Accomplishments, Including Achieving Positive Cash Flow; Company Well Positioned to Capture Global Growth Opportunities | Press release | GlobeNewswire | +3.53% | +13.65% | |
| Form 8-K AMARIN CORP PLC\UK For: Jan 08 | SEC filing · Form 8-K | SEC EDGAR | +3.53% | +13.65% | |
| New REDUCE-IT® Aspirin Analysis Presented at AHA Scientific Sessions 2025 Reinforces VASCEPA®/VAZKEPA® (Icosapent Ethyl) Reduced Cardiovascular Events in High-Risk Patients | Press release | GlobeNewswire | +0.67% | +0.76% | |
| Amarin To Present New Analyses Affirming Robustness of Data from REDUCE-IT and Additional Mechanisms of Action of Eicosapentaenoic Acid (EPA) at American Heart Association (AHA) Scientific Sessions 2025 | Press release | GlobeNewswire | +0.39% | -3.21% | |
| Amarin Reports Third Quarter 2025 Financial Results | Press release | GlobeNewswire | -6.32% | -9.13% | |
| Form 10-Q AMARIN CORP PLC\UK For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | -6.32% | -9.13% | |
| Form 8-K AMARIN CORP PLC\UK For: Oct 29 | SEC filing · Form 8-K | SEC EDGAR | -6.32% | -9.13% | |
| Amarin Issues Statement Supporting FDA’s Action to Revise Labeling for Fenofibrate Drugs Reinforcing a Lack of Cardiovascular Benefit | Press release | GlobeNewswire | -0.24% | -5.96% | |
| Form 8-K AMARIN CORP PLC\UK For: Oct 17 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -1.22% | |
| Amarin to Report Third Quarter 2025 Financial Results and Host Conference Call on October 29, 2025 | Press release | GlobeNewswire | -0.42% | +3.74% | |
| Amarin and HLS Therapeutics Collaborate on Presenting REDUCE-IT® and EPA Mechanistic Data at the Canadian Cardiovascular Congress | Press release | GlobeNewswire | +0.53% | +1.42% | |
| HLS Therapeutics and Amarin Collaborate on Presenting REDUCE-IT® and EPA Mechanistic Data at the Canadian Cardiovascular Congress | Press release | Canada Newswire | +0.53% | +1.42% | |
| Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ESC 2025 | Press release | GlobeNewswire | -0.67% | +1.00% | |
| New REDUCE-IT® Analyses Presented at ESC 2025 Include Data Showing VASCEPA®/VAZKEPA® (Icosapent Ethyl) Therapy Resulted in 9% Fewer Total Hospitalizations & Reduces Cardiovascular Disease Risk in Certain High-Risk Patient Subgroups | Press release | GlobeNewswire | -0.67% | +1.00% | |
| New Analyses from REDUCE-IT® and EPA Mechanistic Data to be Presented at the European Society of Cardiology (ESC) Congress 2025 | Press release | GlobeNewswire | -0.31% | -3.21% | |
| Form EFFECT AMARIN CORP PLC\UK | SEC filing · Form EFFECT | SEC EDGAR | +0.21% | +6.46% | |
| Amarin Reports Second Quarter 2025 Financial Results | Press release | GlobeNewswire | — | +1.15% | |
| Form 10-Q AMARIN CORP PLC\UK For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | — | +1.15% | |
| Form 8-K AMARIN CORP PLC\UK For: Jul 30 | SEC filing · Form 8-K | SEC EDGAR | — | +1.15% | |
| Amarin to Report Second Quarter 2025 Financial Results and Host Conference Call on July 30, 2025 | Press release | GlobeNewswire | +0.62% | +2.23% | |
| Form 8-K/A AMARIN CORP PLC\UK For: Apr 04 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +1.03% | |
| Form 8-K AMARIN CORP PLC\UK For: Jun 20 | SEC filing · Form 8-K | SEC EDGAR | +2.90% | +16.20% | |
| Form 8-K AMARIN CORP PLC\UK For: May 13 | SEC filing · Form 8-K | SEC EDGAR | -0.04% | +0.00% | |
| Amarin Reports First Quarter 2025 Financial Results | Press release | GlobeNewswire | +1.40% | +1.80% | |
| Form 10-Q AMARIN CORP PLC\UK For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +1.40% | +1.80% | |
| Form 8-K AMARIN CORP PLC\UK For: May 07 | SEC filing · Form 8-K | SEC EDGAR | +1.40% | +1.80% | |
| Amarin Regains Compliance with Nasdaq Minimum Bid Price Requirement | Press release | GlobeNewswire | +0.00% | +6.32% | |
| Form 8-K AMARIN CORP PLC\UK For: Apr 29 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +6.32% | |
| Amarin to Report First Quarter 2025 Financial Results and Host Conference Call on May 7, 2025 | Press release | GlobeNewswire | +1.28% | +1.37% | |
| Form ARS AMARIN CORP PLC\UK For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | +3.19% | +2.31% | |
| Form DEF 14A AMARIN CORP PLC\UK For: May 13 | SEC filing · Form DEF | SEC EDGAR | -1.53% | -1.38% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the AMRN section they belong to.
Where else AMRN is measured.
AMRN earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Evoke Pharma, Inc. (EVOK) | 212 | 0.00% | 34% |
| PRECISION THERAPEUTICS INC COMMON (AIPT) | 211 | 0.00% | 46% |
| BioRestorative Therapies, Inc. (BRTX) | 209 | -0.82% | 38% |
| Corvus Pharmaceuticals, Inc. (CRVS) | 208 | -0.32% | 48% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Amarin Corporation plc - American Depositary Shares's median reaction calculated?
Every labeled AMRN news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 211 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 55% of AMRN's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does AMRN's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.